Zentalis Pharmaceuticals financials
$2.72+4.42%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $26.9M | $0.00 | $0.00 | $40.6M | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $26.9M | $0.00 | $0.00 | $40.6M | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | 100.0% | — | — | 100.0% | — | — |
| Operating income | -$44.4M | -$37.9M | -$37.4M | -$33.7M | -$36.1M | -$45.6M | -$49.8M | -$51.4M | -$65.1M | -$24.8M | -$67.9M | -$62.7M |
| Net income | -$42.3M | -$35.4M | -$35.2M | -$26.7M | -$26.9M | -$48.3M | -$47.5M | -$40.2M | -$88.3M | $10.1M | -$60.9M | -$55.5M |
| Net margin | — | — | — | — | — | — | −176.7% | — | — | 24.8% | — | — |
| Diluted EPS | $-0.59 | $-0.50 | $-0.49 | $-0.37 | $-0.37 | $-0.67 | $-0.67 | $-0.56 | $-1.24 | $0.14 | $-0.86 | $-0.79 |
| EBITDA | -$44.2M | -$37.7M | -$37.2M | -$33.6M | -$35.9M | -$37.6M | -$45.8M | -$51.1M | -$64.8M | -$24.4M | -$67.9M | -$62.4M |
| Operating cash flow | -$37.2M | -$33.0M | -$30.9M | -$27.0M | -$34.7M | -$32.6M | -$39.7M | -$44.0M | -$35.1M | -$52.0M | -$40.6M | -$38.7M |
| Free cash flow | -$37.2M | -$33.0M | -$30.9M | -$27.0M | -$34.7M | -$32.6M | -$39.7M | -$44.0M | -$35.3M | -$52.0M | -$40.8M | -$38.8M |
| Diluted shares | 71.3M | 70.3M | 71.7M | 72.1M | 72.0M | 71.7M | 71.0M | 71.1M | 71.0M | 71.2M | 71.0M | 70.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.8M | $31.9M | $36.0M | $39.1M | $37.6M | $41.9M |
| Short-term investments | $149.8M | $179.8M | $209.9M | $241.6M | $265.8M | $290.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $215.3M | $253.1M | $289.0M | $327.3M | $351.7M | $384.0M |
| Total liabilities | $71.7M | $70.4M | $72.8M | $74.4M | $77.2M | $88.6M |
| Shareholders' equity | $143.6M | $182.7M | $216.2M | $252.9M | $274.5M | $295.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology